Study identifier:D8110C00001
ClinicalTrials.gov identifier:NCT04516746
EudraCT identifier:2020-005226-28
CTIS identifier:N/A
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
COVID-19
Phase 3
Yes
-
All
32450
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Feb 2024 by AstraZeneca
AstraZeneca
IQVIA
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
Location
Location
Rochester, NY, United States, 14642
Location
Houston, TX, United States, 77030
Location
Dallas, TX, United States, 75208
Location
North Charleston, SC, United States, 29406
Location
Indianapolis, IN, United States, 46202
Location
San Francisco, CA, United States, 94102
Location
Lake Worth, FL, United States, 33462
Location
Torrance, CA, United States, 90502
Arms | Assigned Interventions |
---|---|
Experimental: AZD1222 Approximately 20,000 participants randomized to the AZD1222 arm | Biological/Vaccine: AZD1222 AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein. |
Placebo Comparator: Placebo Approximately 10,000 participants randomized to the saline placebo arm | Biological/Vaccine: Placebo Commercially available 0.9% (n/V) saline for injection. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.